Shares of Novozymes A/S – (NASDAQ:NVZMY) have been assigned an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

Brokerages have set a twelve-month consensus target price of $50.96 for the company, according to Zacks. Zacks has also assigned Novozymes A/S – an industry rank of 49 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Novozymes A/S – from a “sell” rating to a “hold” rating in a research note on Tuesday, July 19th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Novozymes A/S – (NASDAQ:NVZMY) traded down 0.34% on Tuesday, reaching $43.55. 2,094 shares of the company traded hands. The stock has a market capitalization of $13.08 billion and a price-to-earnings ratio of 30.26. The stock has a 50 day moving average of $44.41 and a 200-day moving average of $46.07. Novozymes A/S – has a 1-year low of $37.98 and a 1-year high of $49.55.

Novozymes A/S – Company Profile

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. In June 2013, the Company restructured its sales areas within those segments. The Household Care (old Household Care Enzymes) area comprises cleaning solutions, laundry, dishwashing and microorganism sales for cleaning solutions.

5 Day Chart for NASDAQ:NVZMY

Get a free copy of the Zacks research report on Novozymes A/S – (NVZMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Novozymes A/S - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S - and related companies with's FREE daily email newsletter.